argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
596.74
+4.92 (0.83%)
Nov 21, 2024, 4:00 PM EST - Market closed
argenx SE Revenue
argenx SE had revenue of $588.88M in the quarter ending September 30, 2024, with 73.28% growth. This brings the company's revenue in the last twelve months to $1.91B, up 85.56% year-over-year. In the year 2023, argenx SE had annual revenue of $1.27B with 187.66% growth.
Revenue (ttm)
$1.91B
Revenue Growth
+85.56%
P/S Ratio
n/a
Revenue / Employee
$1,662,595
Employees
1,148
Market Cap
35.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.27B | 827.59M | 187.66% |
Dec 31, 2022 | 441.01M | -87.26M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | 92.81M | 63.58M | 217.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cardinal Health | 224.45B |
Centene | 146.20B |
Humana | 115.01B |
IQVIA Holdings | 15.32B |
Agilent Technologies | 6.50B |
ResMed | 4.81B |
DexCom | 3.95B |
IDEXX Laboratories | 3.84B |
ARGX News
- 1 day ago - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewsWire
- 2 days ago - Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics - Business Wire
- 10 days ago - argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China - GlobeNewsWire
- 10 days ago - Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Business Wire
- 16 days ago - argenx to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat - Seeking Alpha
- 21 days ago - argenx SE (ARGX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - argenx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire